All News Apontis Pharma AG Deutsche Boerse AG

Equities

APPH

DE000A3CMGM5

Real-time Estimate Tradegate Other stock markets 03:29:52 06/05/2024 pm IST			5-day change	1st Jan Change
8.25 ^EUR	+1.85%		+4.06%	+75.21%

05/04	Apontis Bags Distribution Deal with Novartis Unit for Two Asthma Medications	MT
28/03	Apontis Pharma AG Reports Earnings Results for the Full Year Ended December 31, 2023	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Apontis Bags Distribution Deal with Novartis Unit for Two Asthma Medications	05/04	MT
APONTIS PHARMA enters five-year distribution and marketing agreement with Novartis for two asthma medications and raises forecast	05/04	EQ
APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications	05/04	EQ
Apontis Pharma AG Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
APONTIS PHARMA expects profitable growth again in 2024	28/03	EQ
Apontis Pharma : Earnings Call 2023 Presentation	28/03	PU
Transcript : Apontis Pharma AG - Special Call	06/02
APONTIS PHARMA successfully completes performance and efficiency improvement program	06/02	EQ
APONTIS PHARMA presents details of the restructuring and efficiency program – Nine-month figures for 2023 and new sales and earnings forecast for 2023 published	09/11	EQ
Apontis Pharma Provides Earnings Guidance for the Full Year 2023	09/11	CI
APONTIS PHARMA AG with new forecast 2023 and details on announced restructuring program	09/11	EQ
Apontis Pharma AG Reports Earnings Results for the Half Year Ended June 30, 2023	11/23/11	CI
APONTIS PHARMA confirms preliminary figures – H1 2023 sales and earnings decline	10/23/10	EQ
AstraZeneca Cancels Lung Disease Drug Co-promotion Deal With Apontis Pharma	01/23/01	MT
APONTIS PHARMA: Co-promotion contract with AstraZeneca not to be continued in 2024	31/23/31	EQ
APONTIS PHARMA AG withdraws forecast for fiscal year 2023 and medium-term planning for 2026 – Preparation of program to increase operating performance and efficiency launched	28/23/28	EQ
APONTIS PHARMA AG withdraws forecast for fiscal year 2023 and medium-term planning for 2026	28/23/28	EQ
Apontis Pharma CEO Steps Down; New Chief to Start September	10/23/10	MT
APONTIS PHARMA: CEO Karlheinz Gast resigns for personal reasons - Bruno Wohlschlegel takes over as successor	10/23/10	EQ
Apontis Pharma AG Announces Executive Changes	10/23/10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Apontis Pharma AG Deutsche Boerse AG

Equities

APPH

DE000A3CMGM5

All News

Filters